Covid-19 in Parkinson’s Disease treated by drugs or brain stimulation

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Salari, Mehri
• dc.contributor.author Etemadifar, Masoud
• dc.contributor.author Zali, Alireza
• dc.contributor.author Aminzade, Zahra
• dc.contributor.author Navalpotro-Gómez, Irene
• dc.contributor.author Fateh, Sepand Tehrani
• dc.date.accessioned 2022-07-01T06:46:17Z
• dc.date.available 2022-07-01T06:46:17Z
• dc.date.issued 2021
• dc.description Data de publicació electrónica: 02-08-2021
• dc.description.abstract Purpose: Covid-19 has affected all people, especially those with chronic diseases, including Parkinson's Disease (PD). Covid-19 may affect both motor and neuropsychiatric symptoms of PD patients. We intend to evaluate different aspects of Covid-19 impact on PD patients. Methods: 647 PD patients were evaluated in terms of PD-related and Covid-19-related clinical presentations in addition to past medical history during the pandemic through an online questioner. They were compared with an age-matched control group consist of 673 individuals and a sample of the normal population consist of 1215 individuals. Results: The prevalence of Covid-19 in PD patients was 11.28%. The mortality was 1.23% among PD patients. The prevalence of Covid-19 in PD patients who undergone Deep Brain Stimulation (DBS) was 18.18%. No significant association was found between the duration of disease and the prevalence of Covid-19. A statistically significant higher prevalence of Covid-19 in PD patients who had direct contact with SARS-CoV-19 infected individuals was found. No statistically significant association has been found between the worsening of motor symptoms and Covid-19. PD patients and the normal population may differ in the prevalence of some psychological disorders, including anxiety and sleeping disorders, and Covid-19 may affect the psychological status. Conclusion: PD patients possibly follow tighter preventive protocols, which lead to lower prevalence and severity of Covid-19 and its consequences in these patients. Although it seems Covid-19 does not affect motor and psychological aspects of PD as much as it was expected, more accurate evaluations are suggested in order to clarify such effects.
• dc.format.mimetype application/pdf
• dc.identifier.citation Salari M, Etemadifar M, Zali A, Aminzade Z, Navalpotro-Gomez I, Fateh ST. Covid-19 in Parkinson’s Disease treated by drugs or brain stimulation. Neurologia (Engl Ed). 2021 Aug 2. DOI: 10.1016/j.nrl.2021.07.002
• dc.identifier.doi http://dx.doi.org/10.1016/j.nrl.2021.07.002
• dc.identifier.issn 2173-5808
• dc.identifier.uri http://hdl.handle.net/10230/53654
• dc.language.iso eng
• dc.publisher Elsevier
• dc.rights © 2021 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Neurología. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
• dc.subject.keyword Parkinson's Disease
• dc.subject.keyword Deep brain stimulation
• dc.subject.keyword Covid-19
• dc.subject.keyword SARS-CoV-19
• dc.subject.keyword Pandemic
• dc.title Covid-19 in Parkinson’s Disease treated by drugs or brain stimulation
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/acceptedVersion